Akebia versus United States
Akebia Therapeutics believes it’s being wronged. Medicare has declined to cover its only product, a treatment for anemia related to kidney disease, which has put a drag on revenue. Now, after 12 months of meetings and pleadings, Akebia is taking the government to court.
As STAT’s Nicholas Florko reports, the company is suing CMS over its decision to consider Akebia’s drug, called Auryxia, as a quotidian mineral rather than a pharmaceutical product. The company argues that CMS violated the Administrative Procedure Act in excluding Auryxia from coverage, and the matter will eventually go before a judge.
“Patients deserve better,” Akebia CEO John Butler said. “The president said patients deserve better. His administration is not living up to that commitment and that’s why we had to bring suit.”
Read more.
As STAT’s Nicholas Florko reports, the company is suing CMS over its decision to consider Akebia’s drug, called Auryxia, as a quotidian mineral rather than a pharmaceutical product. The company argues that CMS violated the Administrative Procedure Act in excluding Auryxia from coverage, and the matter will eventually go before a judge.
“Patients deserve better,” Akebia CEO John Butler said. “The president said patients deserve better. His administration is not living up to that commitment and that’s why we had to bring suit.”
Read more.
.png)
No hay comentarios:
Publicar un comentario